Clinical Trial

Feasibility Study of Urinary cfDNA Analysis as a Non-invasive Monitoring Tool in Patients With Prostate or Bladder Cancer

Study acronym: UroDNA
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The UroDNA study is a feasibility study (RIPH category 3) aimed at evaluating the analysis of circulating tumour DNA in urine (urinary cfDNA) as a non-invasive monitoring tool in patients with prostate or bladder cancer. Urine samples will be collected at different times during the course of treatment to define the optimal conditions for cfDNA collection, extraction and analysis, and to explore the detection of tumour mutation profiles. This study does not involve any experimental treatment. Its objective is to validate the technical and clinical feasibility of a molecular monitoring urine test, which could offer a simple and non-invasive alternative to improve the management of urological cancers.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-09.
Trial Details
NCT Number NCT07468838
Lead Sponsor Institut Cancerologie de l'Ouest
Conditions Prostate Cancer, Bladder Cancer
Enrollment 25 participants
Start Date 2026-05
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-16